Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a weight neutral oral antidiabetic drug would earn a 25 percent patient share in the treatment of type 2 diabetes, according to surveyed primary care physicians. Given the prices set for each of the drug profiles and the size of the type 2 diabetic patient population in 2011, a 25 percent patient share would result in sales of $4.1 billion for an agent fitting the report's Minimal Acceptable drug profile and $8.1 billion for an agent fitting the report's Major Achievement profile.

The new report entitled Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia also finds that Novo Nordisk's liraglutide will become the new Decision Resources' proprietary clinical gold standard for the treatment of type 2 diabetes by 2011 as surveyed primary care physicians indicate that liraglutide has competitive advantages in terms of efficacy and safety in comparison to the current gold standard, metformin. Although liraglutide has disadvantages in the area of delivery because of its subcutaneous injectable formulation, its positive efficacy and safety attributes offset its disadvantage in delivery.

"Interviewed primary care physicians also state that liraglutide offers a considerable advantage over other current and emerging type 2 diabetes therapies in terms of weight loss," said Donny Wong, Ph.D., principal analyst at Decision Resources. "As a result, we forecast liraglutide to become the clinical gold standard among the agents covered in our analysis."

About the Report

Type 2 Diabetes: Blockbuster-Bound Januvia Addresses Physicians' Concern over Hypoglycemia is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price-per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (http://www.decisionresources.com/) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   Elizabeth Marshall    Decision Resources    781-296-2563    emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Elizabeth Marshall of Decision Resources, +1-781-296-2563,
emarshall@dresources.com

Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status by 2011 for the Treatment of Diabetic Retinopathy

View Now